Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Irum Khan"'
Autor:
Irum Khan, Soheila Borhani, Marianna Halasi, Carlos J. Camacho, Zarema Arbieva, Binal N. Shah, Andrei L. Gartel, Mikhail S. Chesnokov, Rick Oerlemans
Publikováno v:
Cell Death and Disease, Vol 12, Iss 7, Pp 1-13 (2021)
Cell Death & Disease
Cell Death & Disease
FOXM1 transcription factor is an oncogene and a master regulator of chemoresistance in multiple cancers. Pharmacological inhibition of FOXM1 is a promising approach but has proven to be challenging. We performed a network-centric transcriptomic analy
Publikováno v:
Mol Cancer Ther
Acute myeloid leukemia (AML) is characterized by impaired myeloid lineage differentiation, uncontrolled proliferation, and inhibition of proapoptotic pathways. In spite of a relatively homogeneous clinical disease presentation, risk of long-term surv
Autor:
Jan Philipp Bewersdorf, Blanca Boluda, David Martínez-Cuadrón, Maximilian Stahl, Nikolai A. Podoltsev, Raphael Itzykson, Ellen K. Ritchie, Brendan Yoo, Thomas Cluzeau, Emma Rabinovich, Amer M. Zeidan, Florence Rabian, Ulrich Germing, Rebeca Rodríguez-Veiga, Rory M. Shallis, Steven D. Gore, Isabel Cano, Selina M. Luger, Mikkael A. Sekeres, Christine M. McMahon, Amir T. Fathi, Irum Khan, Evelyn Acuña-Cruz, Vijaya Raj Bhatt, Judith Neukirchen, Sudipto Mukherjee, Mar Tormo, Etienne Lengliné, Emmanuel Raffoux, Pau Montesinos, Wei Wei, Gail J. Roboz, Jayadev Manikkam Umakanthan, Heiko Konig, Adam R. Miller, Andrew M. Brunner
Publikováno v:
Leukemia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
LEUKEMIA
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
LEUKEMIA
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Hyperleukocytosis in acute myeloid leukemia (AML) is associated with inferior outcomes. There is limited high quality evidence to support the benefits of leukapheresis. We retrospectively collected data from patients with newly-diagnosed AML who pres
Autor:
Vaibhav Agrawal, Saad Arain, Gregory S. Calip, Aysenur Esen, Kirk E. Cahill, Shawn Griffin, Olatoyosi Odenike, Ardaman Shergill, Pritesh R. Patel, Heiko Konig, Wendy Stock, Sonia Christian, Karen Sweiss, John G. Quigley, Irum Khan
Publikováno v:
Am J Hematol
Relapsed or refractory acute myeloid leukemia (R/R AML) has a poor prognosis and is best treated with salvage chemotherapy as a bridge to allogeneic stem cell transplant (alloSCT). However, the optimal salvage therapy remains unknown. Here we compare
Autor:
Santosh L. Saraf, Pritesh R. Patel, Nadim Mahmud, Karen Sweiss, David Peace, Annie L. Oh, Robert E. Molokie, Matthew Koshy, Victor R. Gordeuk, Shivi Jain, Michel Gowhari, Sally Campbell-Lee, Damiano Rondelli, John G. Quigley, Irum Khan
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:1759-1765
We report on the screening and development of haploidentical hematopoietic stem cell transplantation (HSCT) for adult patients with clinically aggressive sickle cell disease (SCD) at our institution. Of 50 adult SCD patients referred for HSCT between
Autor:
Andrei L. Gartel, Binal N. Shah, Marianna Halasi, Renáta Váraljai, Irum Khan, Jack L. Arbiser, Ben Hitchinson, Vadim Gaponenko, Elizaveta V. Benevolenskaya
Publikováno v:
Cell Death and Disease, Vol 9, Iss 2, Pp 1-8 (2018)
Cell Death & Disease
Cell Death & Disease
Honokiol is a natural product and an emerging drug for a wide variety of malignancies, including hematopoietic malignancies, sarcomas, and common epithelial tumors. The broad range of activity of honokiol against numerous malignancies with diverse ge
Autor:
Monika J. Stankiewicz, Priya Koppikar, Brady L. Stein, Lauren Diebold, Qiang Wen, Ross L. Levine, Terra L. Lasho, Zan Huang, Sandeep Gurbuxani, Benjamin Goldenson, Ayalew Tefferi, Animesh Pardanani, Christy Finke, John D. Crispino, Rachael Schultz, Irum Khan, Jessica K. Altman, Laure Gilles
Publikováno v:
Leukemia
The majority of patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN) harbor mutations in JAK2 or MPL, which lead to constitutive activation of the JAK/STAT, PI3K, and ERK signaling pathways. JAK inhibitors by themselves are inadequate i